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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of photobiomodulation for people with non-exudative AMD.
B A C K G R O U N D
Description of the condition
Age-related macular degeneration (AMD) is an irreversible, de-
generative eye condition involving the central retina. AMD is the
leading cause of irreversible blindness in people aged 50 years or
older in the UK. It accounts for 50% of blind and partially sighted
registrations (Macular Society 2017).
Clinically, AMD occurs in two forms: dry-AMD where cellular
debris, clinically identifiable as round deposits called drusen ac-
cumulate between the choroid and the retina. This is followed by
gradual retinal cell death, which can be further complicated by the
’wet’ form where blood vessels grow from the choroid underneath
the retina. Wet-AMD is more rapidly advancing, and always has
some degree of dry-AMD present. The exact cause of the underly-
ing disease process is unknown but the major aetiological factors
are oxidative stress, abnormalities in autophagy and heterophagy
and innate immune activation exacerbated by genetic predispo-
sitions. Dry-AMD has early, intermediate and advanced forms;
people with intermediate AMD develop advanced AMD, with
profound central visual loss in over 15% of cases (Klein 2007).
Treatments are evolving for wet-AMD, but there are no licensed
treatments for dry-AMD.
Description of the intervention
Photobiomodulation (PBM) is the process by which low level
light technology affects cellular function. Visible to near-infrared
(NIR) light wavelength can be delivered by low-level lasers or light-
emitting diodes to have beneficial clinical effects.
How the intervention might work
Exposing people with AMD to light ranging from low-intensity
visible to NIR (500 nm to 1000 nm), PBM therapy allows for
high tissue penetration and offers a non-invasive approach for the
treatment of AMD. Mitochondrial cytochrome C oxidase acts as
a photoacceptor for NIR irradiation, resulting in the oxidation
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reduction state of the enzyme. NIR enhances the activity of mi-
tochondrial cytochrome C oxidase and production of adenosine
triphosphate (ATP) in the retina leading to a reduction of free radi-
cal production and oxidative damage (Sivapathasuntharam 2017).
PBM reduces gene expression of retinal stress and inflammatory
markers in the outer retina (Begum 2013; Kokkinopoulos 2013).
Animal studies have shown PBM reduces complement propaga-
tion, increases phagocytosis and improves aged retinal function
(Fuma 2015; Rutar 2012). A review concluded by Fitzgerald et al
shows there is a growing body of preclinical evidence to support
PBM has a disease modifying potential (Fitzgerald 2013). This
has prompted many investigators to conduct clinical trials to as-
sess the efficacy of PBM therapy in improving visual function and
reducing disease progression in people with AMD.
Why it is important to do this review
Consultation with patients and eye care professionals prioritised
the need for a treatment to stop non-exudative AMD progression
(JamesLindAlliance 2013). Each year in theUK70,000people are
diagnosed with advanced AMD, a figure which is expected to rise
to 1.3 million by 2050 (Macular Society 2017). Associated health-
care costs of £16.4 billion are forecasted by 2020 (RNIB 2009).
Over 15% of people with AMD develop advanced AMD, with
profound central visual loss/blindness (Macular Society 2017). In
theUK600,000 people have already progressed to advancedAMD
(Owsley 2007).
AMD limits day-to-day activities due to vision-related impairment
(Berdeaux 2005; Owsley 2006; Scilley 2002). There is currently
no available treatment. An effective and cost-effective intervention
would be of considerable benefit to those globally with this un-
treatable and debilitating condition. PBM offers the possibility of
a safe and non-invasive therapy for AMD. Currently there is wide
heterogeneity of PBM treatment regimens and uncertainty exists
regarding its efficacy. It is important to do this review to obtain
an overall estimate of the effectiveness of PBM treatment in non-
exudative AMD and to assess any harmful effects.
O B J E C T I V E S
To assess the effects of photobiomodulation for people with non-
exudative AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) only in the
review.
Types of participants
We will include studies where participants are aged 50 years or
older and have non-exudative AMD early, intermediate or late as
defined by the Age Related Eye Disease Study (AREDS 2001).
Late stages can feature geographic atrophy; a well-demarcated area
of retinal pigmented epithelium atrophy with or without central
foveal involvement.
Types of interventions
We will include trials where PBM is compared to standard care
with or without sham treatment. We will include studies using
visible to NIR light (500 nm to 1000 nm) delivered by low-
level lasers or light-emitting diodes. Trials that have adequately
described the PBM therapy parameters in terms of wavelength(s),
dose, frequency, duration and coverage will be included.
Standard care consists ofmodifying risk factors; smoking cessation,
nutritional advice and supportive measures; referral to low-vision
services and visual rehabilitation.
Types of outcome measures
Primary outcomes
• Mean best-corrected visual acuity (BCVA) using a logMAR
chart at 12 months follow-up.
Secondary outcomes
• Mean best-corrected visual acuity (BCVA) using LogMar
chart at three months after treatment (range one to three
months).
• Mean contrast sensitivity measured using a Pelli Robson
chart at short- (one to three months) and long-term (12 months)
follow-up.
• Mean near vision between at short- (one to three months)
and long-term (12 months) follow-up.
• Mean low luminance deficit (LLD) score (the difference
between low luminance visual acuity and BCVA) measured in
logMAR chart units at short- (one to three months) and long-
term (12 months) follow-up.
• Mean reading speed at short- (one to three months) and
long-term (12 months) follow-up.
• Mean vision-related quality of life score at short (one to
three months) and long-term (12 months) follow-up measured
using a validated questionnaire.
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If these outcomes are measured using alternative techniques, for
example other visual acuity or contrast sensitivity charts, we will
collect the data and include it in the analysis where possible, e.g.
by converting scales. We will report any cost benefit data reported
in included studies.
Adverse events
The main complication of PBM is visual loss, especially due to
choroidal neovascularisation.Wewill collect all adverse events such
as:
• The proportion of participants with worse vision following
PBM therapy. Worse vision is defined by a loss of 15 or more
Early Treatment Diabetic Retinopathy Study (ETDRS) letters.
• The proportion of participants who developed new
geographic atrophy or progression of geographic atrophy.
• The proportion of participants who developed neovascular
macular degeneration.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist will search
the following electronic databases for randomised controlled trials
and controlled clinical trials. There will be no language or publi-
cation year restrictions.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (which contains the Cochrane Eyes and Vision
Trials Register) in the Cochrane Library (latest issue) (Appendix
1);
• MEDLINE Ovid (1946 to present) (Appendix 2);
• Embase Ovid (1980 to present) (Appendix 3);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch
(Appendix 4);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 5);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp)
(Appendix 6).
Searching other resources
We will review the reference lists of included trial reports and re-
lated systematic reviews to identify additional potentially relevant
trials. We will contact medical device companies conducting stud-
ies on PBM for information about any ongoing or completed but
not published clinical trials. We will search abstracts from the an-
nual meetings of the European VitreoRetinal Society, the Macula
Society, the Retina Society, subspecialty meetings from the Amer-
ican Academy of Ophthalmology, and the American Society of
Retinal Surgeons for ongoing trials.
Data collection and analysis
Selection of studies
Two review authors will screen independently the titles and
abstracts resulting from the searches using web-based software
(Covidence 2015). We will obtain full-text copies of potentially
relevant trials and contact trial investigators for further informa-
tion if required. Discrepancies between authors as to whether or
not studies meet inclusion criteria will be resolved by discussion.
We will document the excluded studies and reasons for exclusion.
For potentially eligible studies identified on trials registers we will
do the following.
• If the study has a completion date more than two years
previously, we will look for publications of this trial and contact
the investigators if necessary to obtain published or unpublished
data from the trial. If eligible, we will include the study in the
review irrespective of whether we can identify a publication.
• If the study has a completion date within two years, or in
the future, we will document the study in the ongoing studies
section.
Data extraction and management
Two review authors will extract data independently using an on-
line form developed by Cochrane Eyes and Vision and using Cov-
idence. We will pre-pilot the data extraction template. We will
resolve discrepancies by discussion. Two attempts will be made to
contact trial investigators for missing data. Data will be directly
imported into Review Manager 5 (RevMan 5) (Review Manager
2014); and the accuracy of the data import will be checked by one
author.
Study characteristics
We will collect the following information on study characteristics
(Appendix 7).
• Study design: parallel group RCT/within-person RCT/one
or both eyes reported
• Participants: country, total number of participants, age, sex,
inclusion and exclusion criteria
• Intervention and comparator details: including number of
people (eyes) randomised to each group
• Intervention details in terms of wavelength, dose, fluence,
intensity, coverage, treatment time, frequency, intervals, total
number of sessions and route of administration
• Primary and secondary outcomes as measured and reported
in the trials
• Adverse events
• Length of follow-up
• Date study conducted
• Sample size and study power
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• Funding and conflicts of interest
• Trial registration, if available
Outcome data
We will extract the following data from each included study for
intervention and comparator groups separately.
• Mean, standard deviation and number of participants on
which outcome measured for continuous variables (visual acuity,
contrast sensitivity, reading speed, LLD score).
• Number of events and number of participants on which
outcome data collected for dichotomous variables (adverse
events).
For multi-arm studies we will use data relevant to our intervention
and comparator groups. If two groups contain relevant data we
will combine groups using the calculator within RevMan 5.
If standard deviation is not available we will use information from
confidence intervals and P values, where possible, to estimate it,
using the RevMan 5 calculator.
Assessment of risk of bias in included studies
Two review authors will assess independently the risk of bias us-
ing Cochrane’s ’Risk of bias’ tool for assessing risk of bias in each
included study (Higgins 2011). We will resolve disagreements by
discussion. We will specifically consider and report on the follow-
ing sources of bias.
• Selection bias (random sequence generation, allocation
concealment): was the sequence of allocation generated using a
random procedure and was the allocation concealed to people
recruiting/enrolling participants and to participants?
• Performance bias (masking of participants and researchers):
were the recipients of care unaware of their assigned
intervention? Were persons providing care unaware of the
assigned intervention?
• Detection bias (masking of outcome assessors). Were
persons evaluating outcomes unaware of the assigned
intervention?
• Attrition bias: were the rates of follow-up and compliance
similar in the groups? Was the analysis by intention to treat and
were there any post-randomisation exclusions?
• Selective outcome reporting bias: is there any evidence that
the outcomes that were measured have not been reported?
We will grade each domain as low risk of bias, high risk of bias or
unclear (lack of information or uncertainty of potential for bias).
We will contact trial investigators for clarification of parameters
graded as ’unclear’.
Measures of treatment effect
We will calculate the mean difference for the following contin-
uous outcomes: visual acuity, contrast sensitivity, reading speed
and LLD score. Where possible, we will check for the skewness of
continuous data (Altman 1996).
We will calculate the risk ratio for adverse events.
Unit of analysis issues
PBM can be applied unilaterally or bilaterally. Usually it is applied
to the affected eye(s). A pilot interventional study showed bilateral
drusen size reduction when an ultra low energy nanosecond laser
was applied unilaterally in AMD-affected eyes (Guymer 2014;
Jobling 2015). Application to only one eye may have an effect in
the fellow eye, although the evidence is unclear and beyond the
scope of this review.
Eyes and people
Trials may randomise one or both eyes to the intervention or
comparator. If people are randomly allocated to treatment but
only one eye per person is included in the trial then there will
not be a ’unit of analysis’ issue. In these cases, we will document
how the eye was selected. If people are randomly allocated to
treatment but both eyes are included and reported, we will analyse
as ’clustered data’ i.e. adjust for within-person correlation. If the
study is a within-person study, i.e. one eye is randomly allocated
to intervention and the other eye receives the comparator, then
we will analyse as paired data. We may have to contact the trial
investigators for further information to do this.
Cross-over trials
Cross-over trials are feasible; however, the wash out period of the
PBM therapy is undetermined which would make designing a
cross-over trial difficult. Where cross-over trials are available only
relevant outcomes of the first phase will be collected.
Dealing with missing data
If possible, we will conduct an intention-to-treat (ITT) analysis.
We will use imputed data if computed by the trial investigators
using an appropriate method, but will not impute missing data
ourselves. If ITT data are not available, we will do an available
case analysis. This assumes that data are missing at random. We
will assess whether this assumption is reasonable by collecting data
from each included trial on the number of participants excluded
or lost to follow-up and reasons for loss to follow-up by treatment
group, if reported.
Assessment of heterogeneity
We will examine the overall characteristics of the studies, in par-
ticular the type of participants and types of interventions, to assess
the extent to which the studies are similar enough to make pooling
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study results sensible. We will look at the forest plots of study re-
sults to see how consistent the results of the studies are, in particu-
lar looking at the size and direction of effects. We will calculate I²
which is the percentage of the variability in effect estimates that is
due to heterogeneity rather than sampling error (chance) (Higgins
2002). We will consider I² values over 50% to indicate substantial
inconsistency but will also consider Chi² P value. As this may have
low power when the number of studies are few we will consider P
< 0.1 to indicate statistical significance of the Chi² test.
Assessment of reporting biases
We will use the ’Risk of bias’ assessment tool to look for selective
or incomplete reporting. See Assessment of risk of bias in included
studies.
If there are 10 trials or more included in a meta-analysis, we will
construct funnel plots and consider tests for asymmetry for assess-
ment of publication bias, according to Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Data synthesis
We will pool data using a random-effects model in RevMan 5. If
there are fewer than three trials in a comparison we will use a fixed-
effect model.
If there is inconsistency between individual study results such that
a pooled result may not be a good summary of the individual trial
results - for example, the effects are in different directions or I² >
50% and P < 0.1 - we will not pool the data but will describe the
pattern of the individual study results.
If there is statistical heterogeneity we may pool the data if all
the effect estimates are in the same direction, such that a pooled
estimate would seem to provide a good summary of the individual
trial results.
Subgroup analysis and investigation of heterogeneity
If there are sufficient trials we will compare the effect of treatment
in the following subgroups.
• early, intermediate and late dry-AMD.
Sensitivity analysis
We will examine the impact of excluding studies at high risk of
bias in one or more domains.
Summary of findings
We will prepare a ’Summary of findings’ table presenting relative
and absolute risks for the following outcomes at 12 months:
• Mean best-corrected visual acuity (BCVA)
• Mean contrast sensitivity
• Mean near vision
• Mean LLD score
• Mean reading speed
• Mean vision-related quality of life score
• Adverse events
Two authors will grade independently the overall certainty of
the evidence for each outcome using the GRADE classification
(GRADEpro 2015).
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Macular Degeneration] explode all trees
#2 MeSH descriptor: [Retinal Degeneration] explode all trees
#3 MeSH descriptor: [Retinal Neovascularization] explode all trees
#4 MeSH descriptor: [Choroidal Neovascularization] explode all trees
#5 MeSH descriptor: [Macula Lutea] explode all trees
#6 macula* near lutea*
#7 (macula* or retina* or choroid*) near/4 degenerat*
#8 (macula* or retina* or choroid*) near/4 neovascul*
#9 AMD or ARMD or maculopath*
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 MeSH descriptor: [Low-Level Light Therapy] this term only
#12 (low near/2 level near/2 light)
#13 (low near/2 level near/2 laser*)
#14 (low near/2 power near/2 laser*)
#15 (low near/2 energy near/2 laser*)
#16 (low near/2 intensity near/2 laser*)
#17 (light near/2 based near/2 technolog*)
#18 light emitting diode*
#19 (LLLT or LLL or LED-T)
#20 (photobiomodulat* or PBM or photomodulat*)
#21 (Gentlewaves or LT-300)
#22 laser* near/2 (irradiat* or phototherap* or biostimulat*)
#23 (phototherap* near/2 infrared)
#24#11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25#10 and #24
Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp retinal degeneration/
14. retinal neovascularization/
15. choroidal neovascularization/
16. exp macula lutea/
17. (macula$ adj2 lutea).tw.
18. ((macul$ or retina$ or choroid$) adj4 degener$).tw.
19. ((macul$ or retina$ or choroid$) adj4 neovasc$).tw.
20. (AMD or ARMD or CNV).tw.
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21. maculopath$.tw.
22. or/13-21
23. Low-Level Light Therapy/
24. (low adj2 level adj2 light).tw.
25. (low adj2 level adj2 laser$).tw.
26. (low adj2 power adj2 laser$).tw.
27. (low adj2 energy adj2 laser$).tw.
28. (low adj2 intensity adj2 laser$).tw.
29. (light adj2 based adj2 technolog$).tw.
30. light emitting diode$.tw.
31. (LLLT or LLL or LED-T).tw.
32. (photobiomodulat$ or PBM or photomodulat$).tw.
33. (Gentlewaves or LT-300).tw.
34. (laser$ adj2 (irradiat$ or phototherap$ or biostimulat$)).tw.
35. (phototherap$ adj2 infrared).tw.
36. or/23-35
37. 22 and 36
38. 12 and 37
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
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31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula degeneration/
34. exp retina degeneration/
35. exp retina neovascularization/
36. exp subretinal neovascularization/
37. (AMD or ARMD or CNV).tw.
38. ((macul$ or retina$ or choroid$) adj4 degener$).tw.
39. ((macul$ or retina$ or choroid$) adj4 neovasc$).tw.
40. exp retina macula lutea/
41. (macula$ adj2 lutea$).tw.
42. maculopath$.tw.
43. or/33-42
44. low level laser therapy/
45. light emitting diode/
46. (low adj2 level adj2 light).tw.
47. (low adj2 level adj2 laser$).tw.
48. (low adj2 power adj2 laser$).tw.
49. (low adj2 energy adj2 laser$).tw.
50. (low adj2 intensity adj2 laser$).tw.
51. (light adj2 based adj2 technolog$).tw.
52. light emitting diode$.tw.
53. (LLLT or LLL or LED-T).tw.
54. (photobiomodulat$ or PBM or photomodulat$).tw.
55. (Gentlewaves or LT-300).tw.
56. (laser$ adj2 (irradiat$ or phototherap$ or biostimulat$)).tw.
57. (phototherap$ adj2 infrared).tw.
58. or/44-57
59. 43 and 58
60. 32 and 59
Appendix 4. ISRCTN search strategy
(Condition: Macular Degeneration OR AMD OR ARMD OR CNV AND Interventions: photobiomodulation OR low level light
OR low level laser)
Appendix 5. ClinicalTrials.gov search strategy
Interventional Studies | Macular Degeneration OR AMD OR ARMD OR CNV | photobiomodulation OR low light OR low laser
Appendix 6. WHO ICTRP search strategy
Condition = Macular Degeneration OR AMD OR ARMD OR CNV AND Interventions = photobiomodulation OR low level light
OR low level laser
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Appendix 7. Data on study characteristics
Mandatory items Optional items
Methods
Study design ·Parallel group RCT i.e. people randomised
to treatment
· Within-person RCT i.e. eyes randomised
to treatment
· Cluster RCT i.e. communities randomised
to treatment
· Cross-over RCT
· Other, specify
Exclusions after randomisation
Losses to follow up
Number randomised/analysed
Howweremissing data handled? e.g., avail-
able case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes or
Unit of randomisation/ unit of analysis
· One eye included in study, specify how
eye selected
· Two eyes included in study, both eyes
received same treatment, briefly specify
how analysed (best/worst/average/both and
adjusted for within person correlation/both
and not adjusted for within person correla-
tion) and specify if mixture one eye and two
eye
· Two eyes included in study, eyes re-
ceived different treatments, specify if cor-
rect pair-matched analysis done
Participants
Country Setting
Ethnic group
Participation rate
Equivalence of baseline characteristics (Y/
N)
Diagnostic criteria
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are only reported for the people who
were followed up only, please indicate.
Number (%) of men and women
Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (n = )
Comparator (n = )
See MECIR 65 and 70
· Number of people randomised to each
group
·Wavelength of photobiomodulation ther-
apy
· Dose, fluence, intensity, coverage, treat-
ment time
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(Continued)
· Frequency, intervals and total number of
sessions
· Route of administration
· Specify whether another intervention was
performed at same time as intervention
Outcomes
Primary and secondary outcomes as defined
in study reports
See MECIR R70
· Best corrected visual acuity at 12 months
· Contrast sensitivity
· Near visual acuity
· Reading speed
· Low luminance deficit score
· Quality of life score
· Cost benefit data (if available)
·The proportion of participants with worse
vision followingphotobiomodulation ther-
apy. Worse vision is defined by a loss
of 15 or more Early Treatment Diabetic
Retinopathy Study (ETDRS) letters
·The proportion of participants who devel-
oped new geographic atrophy or progres-
sion of geographic atrophy
· The proportion of participants who de-
veloped neovascular macular degeneration
Planned/actual length of follow up
· Length of follow up
· Loss to follow up
· Intervals at which outcomes assessed
Notes
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name: (if applicable)
Reported subgroup analyses (Y/N)
Were trial investigators contacted?
Trial Registration Number: (if applicable)Sources of funding
Declaration of interest
See MECIR 69
C O N T R I B U T I O N S O F A U T H O R S
CH prepared the protocol draft and DS reviewed and edited the draft.
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for Ophthalmology.
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